title: Primary breast lymphoma: a single-institute experience in Taiwan.
abstract: BACKGROUND
  Breast is an uncommon location of lymphoma involvement. The most common type of primary breast lymphoma (PBL) is diffuse large B-cell lymphoma (DLBCL). Rituximab is the widely used monoclonal antibody against CD20+ B-cell lymphoma, especially DLBCL. We aimed to analyze the clinical features, prognostic factors, and treatment outcome with or without rituximab in primary breast DLBCL.
  
  
  METHODS
  We retrospectively analyzed patients diagnosed with PBL from October 1987 to March 2012 in our hospital, excluding metastasis by whole-body computed tomography and bone marrow study.
  
  
  RESULTS
  Twenty-three patients were diagnosed with PBL. All were females. Eighteen patients were stage IE and five were stage IIE according to the Ann Arbor staging system. Two patients had lymphoma other than DLBCL. The median age of primary breast DLBCL patients was 48 years (range 27-79). Two were excluded from the analysis due to refusal or ineligibility for chemotherapy. No significant prognostic factor was found. Patients receiving chemotherapy with (RC) or without (C) rituximab were not significantly different in the 5-year overall survival (RC: 57.1%; C: 58.3%; p = 0.457) or progression-free survival (RC: 57.1%; C: 50.0%; p = 0.456). A high incidence of relapse in the central nervous system (CNS) (17.6%) was observed.
  
  
  CONCLUSIONS
  In accordance with prior literature reports, our Taiwanese cohort of primary breast DLBCL seemed younger than those reported in Japan, Korea, and Western societies. Relapse in the CNS was not uncommon. The benefit of rituximab in addition to chemotherapy was not statistically significant. Treatment modality remained to be defined by further large-scale studies.
authors.forename: Che-Wei
authors.initials: CW
authors.lastname: Ou
authors.forename: Lee-Yung
authors.initials: LY
authors.lastname: Shih
authors.forename: Po-Nan
authors.initials: PN
authors.lastname: Wang
authors.forename: Hung
authors.initials: H
authors.lastname: Chang
authors.forename: Ming-Chung
authors.initials: MC
authors.lastname: Kuo
authors.forename: Tzung-Chih
authors.initials: TC
authors.lastname: Tang
authors.forename: Jin-Hou
authors.initials: JH
authors.lastname: Wu
authors.forename: Tung-Liang
authors.initials: TL
authors.lastname: Lin
authors.forename: Yu-Shin
authors.initials: YS
authors.lastname: Hung
authors.affiliation: Division of Hematology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine; School of Medicine, Chang Gung University, Taoyuan, Taiwan.
authors.forename: Po
authors.initials: P
authors.lastname: Dunn
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D012008:Recurrence; D012189:Retrospective Studies; D000069283:Rituximab; D013624:Taiwan; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab